Neuropsychiatry最新文献

{"title":"Quantitative Electroencephalography and Exploding Head Syndrome: A Case Study","authors":"E. Weiler, Rainer Wieg, K. Brill, D. Schneider","doi":"10.4172/Neuropsychiatry.1000558","DOIUrl":"https://doi.org/10.4172/Neuropsychiatry.1000558","url":null,"abstract":"We describe the case of a 65 year old female patient suffering from the exploding head syndrome (EHS). The characteristics of EHS is the perception of sudden loud noises while falling asleep and or during the period of waking up. The syndrome does not cause any pains, however, the medical condition of the female subject is characterized by fear, distress and sleeping problems. Comparison of qEEG data pre and post EHS event revealed significant alterations in the EEG patterns.","PeriodicalId":49013,"journal":{"name":"Neuropsychiatry","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70328973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered Cd8+ T lymphocyte Response Triggered by Arginase 1: Implication for Fatigue Intensification during Localized Radiation Therapy in Prostate Cancer Patients.","authors":"Leorey N Saligan,&nbsp;Nada Lukkahatai,&nbsp;Zhang-Jin Zhang,&nbsp;Chi Wai Cheung,&nbsp;Xiao-Min Wang","doi":"10.4172/Neuropsychiatry.1000454","DOIUrl":"https://doi.org/10.4172/Neuropsychiatry.1000454","url":null,"abstract":"<p><p>Fatigue, the most common side effect of cancer treatments, is observed to intensify during external-beam radiation therapy (EBRT). The underlying molecular mechanisms remain unclear. This study investigated the differentially expressed genes/proteins and their association with fatigue intensification during EBRT. Fatigue scores measured by FACT-F and peripheral blood were collected prior to treatment (baseline D₀), at midpoint (days 19-21, D21) and endpoint (days 38-42, D42) from men (n=30) with non-metastatic prostate cancer undergoing EBRT. RNA extracted from peripheral blood was used for gene expression analysis. Plasma arginase I and arginine were examined using ELISA and liquid chromatography-tandem mass spectrometry. Differences in fatigue scores, gene and protein expression between times points following EBRT were analyzed by one way ANOVA followed by Post Hoc t-test. Fatigue scores decreased significantly from baseline (44.6 ± 8.1) to midpoint (37.3 ± 10.6, <i>p=</i>0.000, low scores indicating high fatigue) and to endpoint (37.4 ± 10.1, p=0.001) during EBRT. <i>ARG1</i> (encoding arginase type 1) was significantly up regulated from baseline to midpoint of EBRT (fold change =2.41, <i>p</i><0.05) whereas genes associated with the adaptive immune functional pathway (<i>CD28, CD27, CCR7, CD3D, CD8A and HLA-DOB</i>) were significantly downregulated >2-fold between the study time points. The changes in gene expression were associated with patient reported fatigue intensity. Moreover, the upregulation of <i>ARG1</i> was negatively correlated with the absolute lymphocyte count (R²=0.561, <i>p</i>=0.01) only in the high level of fatigue group (n=17) during EBRT. Increased <i>ARG1</i> expression is known to result in arginine deficiency, which leads to immunosuppression by impairing lymphocyte proliferation and activation. EBRT-induced <i>ARG1</i> upregulation may play an essential role in fatigue intensification via the arginine deficiency and suppression of T-cell proliferation pathways. These findings may provide novel insights into the molecular-genetic mechanisms underlying the development and intensification of cancer treatment-related fatigue.</p>","PeriodicalId":49013,"journal":{"name":"Neuropsychiatry","volume":"8 4","pages":"1249-1262"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198670/pdf/nihms-991922.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36664563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maladaptive Reorganization in Pain-Related Brain Network Contributing To the Central Post-Stroke Pain","authors":"Xiaoyun Li, Yi Feng, F. Gao","doi":"10.4172/Neuropsychiatry.1000529","DOIUrl":"https://doi.org/10.4172/Neuropsychiatry.1000529","url":null,"abstract":"We collected data from a male CPSP patient with ischemic stroke lesions in the left secondary somatosensory cortex and left posterior insula for the investigation of behavioral-anatomicalfunctional alterations in CPSP, using somatosensory testing, diffusion tensor imaging (DTI), and resting-state functional magnetic resonance imaging (fMRI) techniques. Behavioral results showed that the patient was unable to detect non-nociceptive somatosensory stimuli delivered to the affected hand. Neuroimaging results displayed that compared to healthy controls, the CPSP patient showed (1) the disrupted microstructure (eg, axonal demyelination) in the spino-thalamo-cortical pathway, (2) the hyperactivity in the pain-related brain region (eg, anterior cingulate cortex, ACC) associated with central sensitization, and (3) the dysfunction of pain inhibitory pathways (eg, decreased functional connectivity between ACC and the right dorsolateral prefrontal cortex).","PeriodicalId":49013,"journal":{"name":"Neuropsychiatry","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70328515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurosteroids and oxysterols as potential therapeutic agents for glaucoma and Alzheimer's disease.","authors":"Makoto Ishikawa,&nbsp;Takeshi Yoshitomi,&nbsp;Douglas F Covey,&nbsp;Charles F Zorumski,&nbsp;Yukitoshi Izumi","doi":"10.4172/Neuropsychiatry.1000356","DOIUrl":"https://doi.org/10.4172/Neuropsychiatry.1000356","url":null,"abstract":"<p><p>Glaucoma is one of the most frequent causes of visual impairment worldwide and involves selective damage to retinal ganglion cells (RGCs) resulting in degeneration of neural pathways connecting retina to visual cortex. It is of interest that similarities in pathological changes have been described in Alzheimer's disease (AD), the most common cause of progressive memory loss and dementia in older people. Accumulation of amyloid-beta (Abeta) and hyperphosphorylated tau is thought to contribute to apoptotic neuronal death in Alzheimer's disease, and similar changes have been linked to apoptotic RGC death in glaucoma. Both glaucoma and Alzheimer's disease also suffer from a lack of effective treatments prompting a search for novel therapeutic interventions. Neurosteroids (NSs) (including oxysterols) are endogenous molecules synthesized in the nervous system from cholesterol that can modulate glutamate and GABA receptors, the primary mediators of fast excitatory and inhibitory neurotransmission in the brain, respectively. Because changes in the glutamate and GABA neurotransmitter systems contribute to the pathogenesis of AD and glaucoma, NSs are possible therapeutic targets for these disorders. In this review, we present recent evidence supporting pathological links between Alzheimer's disease and glaucoma, and focus on the possible role of NSs in these diseases and how NSs might be developed for therapeutic purposes.</p>","PeriodicalId":49013,"journal":{"name":"Neuropsychiatry","volume":"8 1","pages":"344-359"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377075/pdf/nihms-983176.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36976165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current electroconvulsive therapy practice and research in the geriatric population.","authors":"Nancy Kerner, Joan Prudic","doi":"10.2217/npy.14.3","DOIUrl":"10.2217/npy.14.3","url":null,"abstract":"<p><p>Electroconvulsive therapy (ECT) is utilized worldwide for various severe and treatment-resistant psychiatric disorders. Research studies have shown that ECT is the most effective and rapid treatment available for elderly patients with depression, bipolar disorder and psychosis. For patients who suffer from intractable catatonia and neuroleptic malignant syndrome, ECT can be life saving. For elderly patients who cannot tolerate or respond poorly to medications and who are at a high risk for drug-induced toxicity or toxic drug interactions, ECT is the safest treatment option. Organic causes are frequently associated with late-life onset of neuropsychiatric conditions, such as parkinsonism, dementia and stroke. ECT has proven to be efficacious even when these conditions are present. During the next decade, research studies should focus on the use of ECT as a synergistic therapy, to enhance other biological and psychological treatments, and prevent symptom relapse and recurrence.</p>","PeriodicalId":49013,"journal":{"name":"Neuropsychiatry","volume":"4 1","pages":"33-54"},"PeriodicalIF":0.0,"publicationDate":"2014-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000084/pdf/nihms567885.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32300915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aging changes and medical complexity in late-life bipolar disorder: emerging research findings that may help advance care.","authors":"Martha Sajatovic,&nbsp;Brent P Forester,&nbsp;Ariel Gildengers,&nbsp;Benoit H Mulsant","doi":"10.2217/npy.13.78","DOIUrl":"https://doi.org/10.2217/npy.13.78","url":null,"abstract":"<p><p>Demographic trends globally point in the direction of increasing numbers of older people with serious and chronic mental disorders, such as bipolar disorder (BD). While there has been growing sophistication and understanding in treatments for BD generally, data specific to older people with BD are limited. Recent reviews, secondary analyses and some new research confirm complexity and aging-related issues relevant to later-life BD. Confounding variables that must be considered when studying older BD individuals include clinical heterogeneity, medical comorbidity, cognitive impairment and concomitant psychotropic medication. This article will review current and emerging data on aging- and disease-related issues that complicate assessment and treatment of older individuals with BD. We will discuss common comorbid medical conditions that affect BD elders, how aging may affect cognition and treatment, including the effects of lithium and other psychotropic drugs on the aging brain, and recent research using neuroimaging techniques that may shed light on understanding the mechanisms of illness progression and on treatment response. Finally, we will discuss implications for future work in geriatric BD.</p>","PeriodicalId":49013,"journal":{"name":"Neuropsychiatry","volume":"3 6","pages":"621-633"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/npy.13.78","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32484147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in the Definition of ADHD in DSM-5: Subtle but Important.","authors":"Jeffery N Epstein,&nbsp;Richard E A Loren","doi":"10.2217/npy.13.59","DOIUrl":"https://doi.org/10.2217/npy.13.59","url":null,"abstract":"","PeriodicalId":49013,"journal":{"name":"Neuropsychiatry","volume":"3 5","pages":"455-458"},"PeriodicalIF":0.0,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/npy.13.59","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32188384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics of high-functioning youth with autism spectrum disorder and anxiety.","authors":"Danielle Ung,&nbsp;Jeffrey J Wood,&nbsp;Jill Ehrenreich-May,&nbsp;Elysse B Arnold,&nbsp;Cori Fuji,&nbsp;Patricia Renno,&nbsp;Tanya K Murphy,&nbsp;Adam B Lewin,&nbsp;P Jane Mutch,&nbsp;Eric A Storch","doi":"10.2217/npy.13.9","DOIUrl":"https://doi.org/10.2217/npy.13.9","url":null,"abstract":"<p><strong>Aim & methods: </strong>Clinical characteristics were examined in 108 high-functioning youth (children with a full IQ scale of at least 70) with an autism spectrum disorder (ASD; aged 7-15 years) who were presenting for inclusion in one of four clinical trials examining the efficacy of cognitive behavioral therapy in youth with ASD and anxiety.</p><p><strong>Results: </strong>We present baseline characteristics of this cohort, including prevalence rates of anxiety and comorbid disorders, and correlates of anxiety (e.g., comorbid diagnoses, impairment, anxiety severity and mental health services received) as a function of age and ASD diagnosis in treatment-seeking youth. Primary anxiety disorders were: 41.7% (n = 45) social phobia, 25.9% (n = 28) generalized anxiety disorder, 15.7% (n = 17) separation anxiety disorder, 12.0% (n = 13) obsessive-compulsive disorder and 4.6% (n = 5) specific phobia. Overall, 91.6% of participants (n = 99) met criteria for two or more anxiety disorders. Parents reported considerable functional impairment as measured by the Columbia Impairment Scale and anxiety severity as measured by the Pediatric Anxiety Rating Scale; this did not statistically differ as a function of ASD diagnosis or age. Anxiety severity, the number of comorbid anxiety diagnoses and total comorbid diagnoses were directly associated with parent-reported child impairment. Youth with ASD and anxiety present as a heterogeneous cohort with significant impairments and complex diagnostic presentations.</p><p><strong>Conclusion: </strong>These data provide information about the nature of anxiety in youth with ASD, which may foster the development of tailored treatment protocols.</p>","PeriodicalId":49013,"journal":{"name":"Neuropsychiatry","volume":"3 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/npy.13.9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31823045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward an exportable parent training program for disruptive behaviors in autism spectrum disorders.","authors":"Karen Bearss, Luc Lecavalier, Noha Minshawi, Cynthia Johnson, Tristram Smith, Benjamin Handen, Denis Sukhodolsky, Michael Aman, Naomi Swiezy, Eric Butter, Lawrence Scahill","doi":"10.2217/npy.13.14","DOIUrl":"10.2217/npy.13.14","url":null,"abstract":"<p><p>Autism spectrum disorders (ASD) are chronic conditions of early childhood onset characterized by profound deficits in social interaction, impaired communication, and repetitive behavior. The prevalence of ASD is now estimated to be 1 in 88 children. As the number of identified cases of ASD has grown, so have the challenges of serving these children and their families. Unfortunately, the empirical foundation for many interventions for this population is not firmly established. Thus, there is a pressing need to conduct trials that will expand the evidence base and guide clinical treatment. Investigators from the Research Units in Pediatric Psychopharmacology (RUPP; Indiana University, Ohio State University, University of Pittsburgh, Yale University) followed a treatment development model outlined by an NIMH ad hoc committee to develop and test a parent training (PT) treatment manual for children with ASD accompanied by disruptive behavior problems. This article describes the process of manual development and cross-site therapist training, establishment and maintenance of treatment integrity, assessment of treatment acceptance by families as well as primary outcomes of three trials. Results suggest the structured PT program can be delivered with a high degree of fidelity within and across therapists, is acceptable to parents and can produce significant reductions in disruptive behaviors in children with ASD.</p>","PeriodicalId":49013,"journal":{"name":"Neuropsychiatry","volume":"3 2","pages":"169-180"},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678377/pdf/nihms476451.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31511627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is 'bench-to-bedside' realistic for autism? An integrative neuroscience approach.","authors":"Melissa D Bauman,&nbsp;Cynthia M Schumann","doi":"10.2217/npy.13.18","DOIUrl":"https://doi.org/10.2217/npy.13.18","url":null,"abstract":"<p><p>Given the prevalence and societal impact of autism spectrum disorder (ASD), there is an urgent need to develop innovative treatments that will improve core social deficits, for which there is currently no reliable pharmacological treatment, prevention or cure. Development of novel biological interventions will depend upon the successful translation of basic neuroscience research into safe and effective medicines. This article outlines steps to bring neuroscience research from 'the bench' to treatment at 'bedside', from phenotyping the disorder to animal models to patient treatment. Although these steps appear simplistic, this is a daunting challenge because of the inherent complexity of the human brain, our lack of understanding of disease neurobiology underlying ASD, and the incredible heterogeneity of the disorder. For ASD, perhaps more than any other neurological or psychiatric disorder, progress will depend on integrative multidisciplinary approaches between basic scientists from varying neuroscience disciplines and clinicians to make 'bench to bedside' treatment a reality.</p>","PeriodicalId":49013,"journal":{"name":"Neuropsychiatry","volume":"3 2","pages":"159-168"},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/npy.13.18","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31703532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}